Global Cardiovascular Devices Market to Reach $101.6 Billion by 2030, Says BCC Research Analyst

“Valued at $72.4 billion in 2025, the global market is forecast to reach $101.6 billion by 2030 as minimally invasive procedures and remote cardiac monitoring gain adoption.”

Boston, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The global cardiovascular devices market is undergoing a period of profound structural expansion, propelled by an aging global population, rising disease burden, and a wave of next-generation therapeutic technologies. BCC Research's latest analysis, Cardiovascular Devices: Global Markets to 2030, provides comprehensive market sizing, segmentation, and competitive intelligence covering the full spectrum of cardiovascular device categories through the forecast period.

Key Findings

• Market Expansion Driven by Chronic Disease Prevalence: The escalating global burden of arrhythmias, heart failure, and coronary artery disease — exacerbated by hypertension, obesity, and sedentary lifestyles — is generating substantial and sustained demand for pacemakers, interventional devices, stents, and diagnostic platforms across both developed and emerging healthcare markets.
• Procedure Volume Growth Underpins Device Demand: Increasing procedure volumes for transcatheter aortic valve replacement (TAVR), structural heart interventions, and electrophysiology ablation are broadening the clinical addressable market. The December 2025 FDA approval of the SAPIEN M3 transcatheter mitral valve replacement system (Edwards Lifesciences) marks a pivotal expansion of catheter-based structural heart therapy.
• Minimally Invasive and Leadless Technologies Reshaping Clinical Standards: Catheter-based procedures are displacing open surgical approaches, reducing patient risk and widening treatment eligibility. Leadless pacemakers — including Medtronic's Micra AV2 and Micra VR2 and Abbott's AVEIR DR dual-chamber device — are addressing longstanding lead-related complications such as infection, mechanical failure, and device malfunction, driving adoption across electrophysiology departments globally.
• Pulsed Field Ablation Emerging as a Defining Electrophysiology Modality: PFA systems — including Boston Scientific's FARAPULSE, Medtronic's PulseSelect, and Abbott's Volt PFA System — are rapidly gaining clinical traction, offering tissue-selective energy delivery that improves procedural safety profiles relative to thermal ablation techniques.
• AI and Wearable Platforms Transforming Early Detection: AI-enabled cardiac monitoring solutions, including Philips' Cardiologs analytics, Biotronik's SmartECG AI (BIOMONITOR IV), and iRhythm's Zio patch, are shifting the diagnostic paradigm toward continuous, ambulatory, and remote patient management. Investigational technologies such as the Idoven ASSIST project's AI-based acute myocardial infarction diagnosis tools signal further disruption ahead.
• Competitive Landscape Dominated by Global MedTech Leaders: The market is anchored by Abbott, Boston Scientific, Medtronic, Edwards Lifesciences, Terumo, Koninklijke Philips, Siemens Healthineers, and GE HealthCare, with emerging innovators — including BiVACOR, EBR Systems, Xeltis, FineHeart, and Kardium — advancing next-generation implantable and bioresorbable solutions.

Market Drivers

The cardiovascular devices market is underpinned by converging structural forces that show little sign of abating. Demographic aging across North America, Europe, and Asia-Pacific is increasing the prevalence of conditions requiring long-term device-based management, while national health programs — including Australia's Medicare Benefits Schedule, Pharmaceutical Benefits Scheme, and Medical Research Future Fund — are reinforcing healthcare infrastructure investment and accelerating device adoption pathways.
Technological innovation is simultaneously expanding the clinical frontier. Bioresorbable stents using PLLA polymer and metallic (magnesium, zinc, iron) substrates, gene-eluting and 4D-printed personalized stents with self-reporting sensors, biodegradable PFO closure devices, and fully implantable heart failure solutions such as FineHeart's FlowMaker and BiVACOR's Total Artificial Heart represent a generation of devices that could redefine chronic cardiovascular management. Northwestern University's world's smallest injectable, biocompatible, and dissolvable pacemaker — designed for neonatal temporary pacing — further illustrates the breadth of innovation underway.

Investment Considerations

Investors evaluating the cardiovascular devices space should recognize both the compelling long-term demand thesis and near-term headwinds requiring careful navigation. U.S. tariffs on imported medical device components represent a material cost pressure: Medtronic has guided for approximately $185 million in tariff-related impact, while Boston Scientific anticipates $100 million in additional costs in 2025, compressing margins for major market participants. Regulatory complexity — particularly EU MDR expert panel requirements for Class III implantable devices — adds time and capital to approval timelines, disproportionately affecting smaller innovators. Despite these pressures, companies with diversified geographic revenue, vertically integrated manufacturing, and platforms spanning diagnostics, implantables, and remote monitoring — including Abbott, Boston Scientific, and Medtronic — are best positioned to capture structural market growth. Early-stage innovators in bioresorbable scaffolds, leadless CRM, and AI-driven diagnostics offer higher-risk, higher-upside positioning for growth-oriented portfolios.

About the Report

Cardiovascular Devices: Global Markets to 2030 (Report Code: HLC210B) delivers comprehensive market sizing, segmentation by device category and geography, competitive intelligence, and forecasts through 2030 across the full cardiovascular devices value chain.

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process.
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

BCC Research LLC
50 Milk St., Ste. 16, Boston, MA 02109
press@bccresearch.com  |  +1 781-489-7301
www.bccresearch.com